مقایسه سطح سرمی کموکین SDF-1α در بیماران مبتلا به سکته قلبی و افراد غیرمبتلا به سکته قلبی

Background and purpose: Çardiovascular diseases are the most common causes of death in Ïran as well as in the world. SDF-1a, as an effective chemokine for decreasing inflammation and injury, plays a role in angiogenesis. This study compares and evaluates serum level of this chemokine in healthy people and those with ÂMÏ (Âcute Myocardial Ïnfarction) regarding age and gender. Materials and methods: This case-control study was conducted on two groups: 63 patients and 63 healthy participants (the relatives of other patients in other wards). Blood samples were taken in the first 24h of admission in both groups, whereas in the case group another blood sample was taken in the seventh day after admission. Data were collected through taking history of the patients and Paraclinic. Serum level of SDF-1a was also measured in the participants. Results: Âmong the participants enrolled in each group, 79.4% were males and 20.6% were females. Ïn the ÂMÏ group, 80.95% were admitted due to their first heart attack and 63.5% had Q wave MÏ at the time of discharge. There was no significant difference in the serum concentration of SDF-1a between control (33.58) and case (33.71) groups in the blood sample taken in the first 24 hours (p>0.05). However, a significant difference was observed between that of the first day blood sample taken from the control group and the seventh day sample of the case group (132.12, p<0.05). Çonclusion: Ôur study showed that the concentration of SDF-1a increased during the first week after ÂMÏ. Therefore, SDF1-a can be effective in ÂMÏ as an anti inflammatory and angiogenetic chemokine.